Nadroparin Completed Phase 4 Trials for Thrombosis / COVID / Deep Vein Thrombosis / Coronavirus Disease 2019 (COVID‑19) / Pulmonary Embolism Prevention

Indications	Status	Purpose	Phase
DBCOND0020122 (Thrombosis) DBCOND0127821 (COVID) DBCOND0029964 (Deep Vein Thrombosis) DBCOND0129755 (Coronavirus Disease 2019 (COVID‑19)) DBCOND0027915 (Pulmonary Embolism)	Completed	Prevention	4

clinicaltrials.gov Identifier	Title	Drugs
NCT04373707	Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19	Dalteparin (DB06779) Enoxaparin (DB01225) Nadroparin (DB08813) Tinzaparin (DB06822)